Financial Transaction:
Series C
Chromacode Inc
Note
Investment to support the launch of ChromaCode’s multi-drug resistant bacteria panel, tick-borne pathogen panel, SARS-CoV-2 panel, and upper-respiratory-tract infection panel.
Round participants
Investor | Country | Notes | |
---|---|---|---|
![]() |
Adjuvant Capital |
Initial investment. | |
![]() |
Domain Associates LLCVenture capital firm focused on life sciences companies. |
United States | Initial investment. |
![]() |
New Enterprise Associates Inc(NEA)Global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. |
United States | Initial investment. |
![]() |
Northpond VenturesScience-driven venture capital firm headquartered in Bethesda, Maryland. |
United States | Initial investment. |